Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. - Wikidata - awgldk - TriplyDB

Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial.

Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial.

http://www.wikidata.org/entity/Q46644252

about

Adverse events associated with testosterone administration A practical guide to diagnosis, management and treatment of testosterone deficiency for Canadian physicians Testosterone for the aging male; current evidence and recommended practice Will testosterone replacement therapy become a new treatment of chronic heart failure? A review based on 8 clinical trials Androgen receptor (AR) in cardiovascular diseases Cardiovascular effects of hormone therapy for prostate cancer Testosterone and the cardiovascular system: a comprehensive review of the clinical literature Andropause: Current concepts Sarcopenia in heart failure: mechanisms and therapeutic strategies Sex hormones are associated with right ventricular structure and function: The MESA-right ventricle study Mechanistic Pathways of Sex Differences in Cardiovascular Disease.Study protocol to investigate the effects of testosterone therapy as an adjunct to exercise rehabilitation in hypogonadal males with chronic heart failure.Beneficial effects of testosterone therapy on functional capacity, cardiovascular parameters, and quality of life in patients with congestive heart failure.Serum testosterone levels and mortality in men with CKD stages 3-4 Risk factors associated with cardiovascular events during testosterone administration in older men with mobility limitation.Late-onset hypogonadism: current concepts and controversies of pathogenesis, diagnosis and treatment Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis.Skeletal myopathy in patients with chronic heart failure: significance of anabolic-androgenic hormones Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials.Muscle wasting and cachexia in heart failure: mechanisms and therapies.Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes Testosterone suppresses ventricular remodeling and improves left ventricular function in rats following myocardial infarction.Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation Growth hormone, insulin-like growth factor 1, and insulin signaling-a pharmacological target in body wasting and cachexia Predictive value of serum testosterone for type 2 diabetes risk assessment in men Central and peripheral testosterone effects in men with heart failure: An approach for cardiovascular research.Testosterone deficiency increases hospital readmission and mortality rates in male patients with heart failure.Treatment of Men for "Low Testosterone": A Systematic Review.Molecular and cellular mechanisms of skeletal muscle atrophy: an update.Controversies in testosterone replacement therapy: testosterone and cardiovascular disease.Are men at risk? The role of testosterone in cardiovascular morbidity.The triad of erectile dysfunction, hypogonadism and the metabolic syndrome.Gender-based differences in cardiac diseases Androgen therapy and atherosclerotic cardiovascular disease.Testosterone Attenuates Age-Related Fall in Aerobic Function in Mobility Limited Older Men With Low Testosterone Testosterone replacement therapy.Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial Testosterone and cardiovascular disease in men.An old emperor finds new clothing: rejuvenation in our time.Testosterone level and mortality in elderly men with systolic chronic heart failure.

P2860

Q24601802-44DF238B-3879-416F-864C-2722ABDED4B1 Q24602168-AAF413B8-0BFE-4E54-84A5-EE3366E58BA7 Q24647679-8620364A-59A0-43F2-B00F-0ECF19E18ACF Q26750979-B1E55B58-0A69-44DE-B0B7-2AB96CC0C8BB Q26771962-BA6574B6-7393-4CD7-8FE1-29B5BE13F1C6 Q26801112-6C6C97C3-333A-438D-955A-204B6831A885 Q27000507-8FF51079-324F-4DB2-B7DD-FFD1AC93078A Q27024886-2CD89928-DD79-42F9-82B4-BAEF6D7FC321 Q28066237-9BD5C5D3-EBB0-49AA-874F-37B530FF2076 Q28388122-B4C6610D-EC08-4D58-A098-AA396C22AD54 Q30241924-6AE3C61C-C2B6-46C7-B518-F5A92977E2DD Q33265109-376F13FF-16EB-473B-BAAA-C0E2F0F4BF61 Q33943721-38511CBB-2EEC-459E-B68E-51378AF3BB70 Q34084357-0E181343-5C4B-44B5-A034-B88451E69571 Q34259431-FD189E7C-E661-4B31-92AD-DCCC3BA01FC6 Q34396808-3A384560-C0F2-4A8F-A732-C400AE24AA2B Q34578805-4213647B-6304-4223-9665-A3B7CBD19F40 Q34590954-D8D3AA4F-9837-492F-AE25-260657FABD2D Q34676945-71E46F86-7256-4218-A76D-1F9CBB2C8D59 Q34681621-DEFD8131-28D2-4206-8165-9270B9659E3A Q35060256-633D34EB-D986-43A7-A205-E30C60C40137 Q35159728-DD34ED6F-7E08-4B1F-B03F-5C2DADCD72C9 Q35459531-BC910ADE-DF2F-4F0F-8E32-1B71DF9D9076 Q35569439-4C8951FB-7FD5-4FD7-B203-8CE85FE9D7A1 Q36031730-375D9366-6023-41A0-966E-C99754465CDF Q36080502-FA9F2FF0-C59F-485E-A2B1-C61C93FD0A1C Q36117018-52F55005-64D8-40F3-BDE0-47F081A79050 Q36139976-547A2B8C-F02B-44B8-A4BE-F6E8AF31BDCA Q36179105-63A84AF4-BA2E-440C-B89A-AB1E310F43DD Q36293066-1AAE4F40-FC02-4C04-8A8D-15E21400E448 Q36366063-B7B94EB8-C152-44F6-A1CC-36C8F206879A Q36575143-18ED8703-B4E1-4DD3-9FB3-010091302C90 Q36681974-9910F943-03A1-42C0-BDAE-E6ACF14466F0 Q36766910-FF0DB9F7-5A73-4E57-B3BA-B375B6BAABA1 Q36965280-AB8E023D-E378-4BB1-A87F-06DBF8E4AB1F Q36987403-3E6A50B3-E435-4A21-BA6B-C243D6E38375 Q37037560-5D0B5653-BE09-4E98-94F2-F308C7ED7155 Q37037827-FE2C23B5-72A3-4D01-88F1-0FC887BBDCEF Q37084746-C021BBE3-E5ED-47FA-A95C-CC40E354FE18 Q37085277-467A9E51-D8AC-4643-BAD5-977398BB832A

P2860

Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial.

http://www.wikidata.org/entity/Q46644252

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Testosterone therapy in men wi ...... ized placebo controlled trial.

@en

Testosterone therapy in men wi ...... ized placebo controlled trial.

@nl

type

label

Testosterone therapy in men wi ...... ized placebo controlled trial.

@en

Testosterone therapy in men wi ...... ized placebo controlled trial.

@nl

prefLabel

Testosterone therapy in men wi ...... ized placebo controlled trial.

@en

Testosterone therapy in men wi ...... ized placebo controlled trial.

@nl

P1433

Q46644252-60D90F79-B9CD-4275-AC32-0D669F401A67

P1476

Q46644252-DC5A7B05-C4A7-41DF-A7A2-19C513306251

P2093

Q46644252-235CCD52-1C54-401B-9537-AB8A553F00D1

Q46644252-37618AD4-4D2E-44F3-9AB8-2499999A395D

Q46644252-4BD45C3C-4E75-491E-9ABC-F5FE76555CB6

Q46644252-5A03D793-9C2D-4537-88F2-675F9298DEA0

Q46644252-E7DCEA61-2718-4DE7-A742-6AB46B37DA5E

Q46644252-F23EA6EA-8B74-4A57-80D2-F2AD32547067

P2860

Q46644252-129BBB19-03CE-40D2-8B6C-721C176C02A5

Q46644252-16B61EFB-0935-4CF1-8168-22CF2FD2877B

Q46644252-1936F131-9306-48FE-9D5F-73DF6497377D

Q46644252-1FEABC88-321D-4560-A62C-68EEA4D2138E

Q46644252-20B38C23-B3C0-4E5C-A25A-D4391C1B065C

Q46644252-22AD183E-DF56-4EE5-99D9-AB6B6F27CCAA

Q46644252-3422C167-F4EF-4181-A78E-05E2DAC8753C

Q46644252-39D96B27-B838-4AA0-99DC-9BC9B6543BE0

Q46644252-4E6B00EF-2C23-4F72-B6A5-5A5187129574

Q46644252-4EE88CB4-F2BD-449B-8BA5-6C4D2C55ACEA

P304

Q46644252-413B7277-D34D-4F69-AE26-52FBF44E7879

P31

Q46644252-AEE111AD-F748-4AD7-8527-1C414677FBA2

P356

Q46644252-EAD034B2-435A-4C8B-BC39-03476A90253A

P433

Q46644252-D01DBFBE-2DBD-4BB1-82E4-3794A87EBECE

P478

Q46644252-F9EFDDA0-A365-4DFC-B800-A4D177D1A9B4

P577

Q46644252-BAF91E1B-C8DE-4F59-967C-F701F8C36BE6

P5875

Q46644252-D464352B-48FC-4F95-87E6-56D0F1D6B6F4

P698

Q46644252-2BB36A0F-E458-4521-8628-EE95E1351155

P921

Q46644252-112C9D82-74DF-4F9D-BAC3-BE6A415BF67F

Q46644252-B617BA32-9928-4986-8D5F-535B79646FFE

P356

P1433

European Heart Journal

P1476

Testosterone therapy in men wi ...... ized placebo controlled trial.

@en

P2093

Chris J Malkin

http://www.w3.org/2001/XMLSchema#string

Edwin J R van Beek

http://www.w3.org/2001/XMLSchema#string

John N West

http://www.w3.org/2001/XMLSchema#string

Kevin S Channer

http://www.w3.org/2001/XMLSchema#string

Peter J Pugh

http://www.w3.org/2001/XMLSchema#string

T Hugh Jones

http://www.w3.org/2001/XMLSchema#string

P2860

Decreasing one-year mortality and hospitalization rates for heart failure in Sweden; Data from the Swedish Hospital Discharge Registry 1988 to 2000.

Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium.

Epidemiology, aetiology, and prognosis of heart failure.

Anabolic steroid use in body builders: an echocardiographic study of left ventricle morphology and function.

Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.

Hormonal profile in patients with congestive heart failure.

Depressive symptoms are the strongest predictors of short-term declines in health status in patients with heart failure.

Proof of the effect of testosterone on skeletal muscle.

Incremental shuttle walk test in the assessment of patients for heart transplantation.

The cardiovascular effects of erythropoietin.

P304

57-64

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHI443

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2005-08-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7667637

http://www.w3.org/2001/XMLSchema#string

P698

16093267

http://www.w3.org/2001/XMLSchema#string

P921